A new publication referencing insulin degludec was published on October 1, 2026. The article, titled "A Novel Paradigm for Adult-Onset Type 1 Diabetes: Once-Weekly Basal Insulin and SGLT-2 Inhibition to Harness Residual β-Cell Function," appeared in the journal Diabetes/metabolism research and reviews.
The publication is indexed under PubMed ID 42937021. No additional details such as study design, outcomes, or conclusions were provided in the available event data. This brief reports only the existence and metadata of the publication, not its content or findings.
Insulin degludec remains an approved compound. Readers interested in the broader context of this compound, including its regulatory status and prior publications, can consult the compound overview for further information.